ArticleFrontiers in oncology2025
Explainable machine learning model predicts response to adjuvant therapy after radical cystectomy in bladder cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Radical cystectomy (RC) is the standard treatment for muscle-invasive and select high-risk non-muscle-invasive bladder cancer. Despite definitive surgery, recurrence and progression remain major clinical concerns. Adjuvant chemotherapy and immunotherapy may improve outcomes, but therapeutic response varies due to tumor heterogeneity. Robust predictive models are needed to guide individualized treatment strategies. Methods: This study retrospectively analyzed bladder cancer patients undergoing RC. Data included tumor morphology (e.g., vascular and perineural invasion), demographic variables (e.g., age, sex), and molecular markers (e.g., PD-L1, HER2, GATA3). LASSO regression identified key features, followed by model development using nine machine learning algorithms, including XGBoost and LightGBM. Model performance was assessed via area under the ROC curve (AUC), and Shapley Additive Explanations (SHAP) were used for model interpretability. Results: The random forest model achieved the highest predictive performance (AUC = 0.92 in training; 0.74 in testing). SHAP analysis identified vascular invasion, perineural invasion, and PD-L1/HER2 expression as major contributors. Decision curve analysis showed favorable net benefit within a moderate-risk threshold. Conclusions: A machine learning model integrating pathological, demographic, and molecular features demonstrates promising potential to predict response to adjuvant therapy post-RC in bladder cancer. Decreased performance in the external test cohort highlights the need for further validation. Prospective studies incorporating multi-center and longitudinal data are warranted to enhance model generalizability and clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.